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One way to develop innovative approaches for the treatment of chronic diseases is
to exploit the biology of the resolution of inflammation. With this terminology, we
identify the integrated and complex network of mediators and pathways that ensure
a timely and spatially regulated inflammatory response. Pro-resolving mediators act
on specific receptors. This provides an opportunity for developing a new arm of phar-
macology we have termed “resolution pharmacology.” Here we present the reasoning
behind the need to develop new medicines based on resolution and use a prototype
GPCR as an example. Understanding how the formyl peptide receptor type 2 (FPR2)
operates in a cell-specific manner can guide the development of agonists as new
therapeutics that could be of benefit as a therapy or co-therapy for several diseases
that affect our society. FPR2 agonists would be among the first drugs to establish
“resolution pharmacology” as the pharmacological approach for the third decade of
the millennium.
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1 | INTRODUCTION
The formyl peptide receptor type 2 (FPR2) is a member of the formyl
peptide receptor (FPR) family. The human FPR family is clustered on
chromosome 19 and encodes a family of three Class A GPCRs
(Ye et al., 2009). This class of receptors is characterised by a short N-
terminal region, an NPXXY motif in transmembrane (TM) region 7 and
an E/DRY motif that bridges TM3 and TM6 stabilising inactive recep-
tor conformations. FPRs play a critical role in innate immune
responses through recognition of pathogen-associated molecular
patterns (PAMPs) and damage-associated molecular patterns
(DAMPs). FPR2 is highly expressed in myeloid cells and also in cells of
diverse origin including endothelia, epithelia, smooth muscle cells,
chondrocytes and fibroblasts.
FPR2 displays many intriguing physiological and pharmacological
responses as reflected, initially, by its activation by diverse ligands
including proteins, peptides and lipids (Perretti et al., 2002). Thus,
FPR2 is referred to as ALX, an acronym for the lipoxin A4 (LXA4)
receptor and, indeed, the terminology ALX/FPR2 or FPR2/ALX should
be used to identify it when activated by lipid or protein agonists,
respectively (Ye et al., 2009). Intriguingly, FPR2 also conveys pro-
inflammatory effects in response to specific ligands, like the acute-
phase protein serum amyloid A. It is plausible that ligand-specific
receptor conformational changes associated with downstream signal-
ling are the main reason for the divergent properties reported in the
literature (e.g. T. Chen et al., 2020). Similarly, a degree of versatility
Abbreviations: ALX, lipoxin A4 receptor; AnxA1, annexin A1; COVID-19, coronavirus disease
2019; FPR, formyl peptide receptor; FPR2, formyl peptide receptor type 2; TM,
transmembrane.
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has been reported with respect to signalling pathways: classically
associated to an inhibitory G protein, FPR2 signalling provokes forma-
tion of IP3 and calcium fluxes together with an involvement of
MAPKs. It is now evident that it can engage distinct G proteins and
hence activates different signalling cascades, presumably in a target
cell-specific manner (Inoue et al., 2019). Congruently, FPR2-depedent
cAMP activation, presumably following engagement with a G protein
containing a Gs alpha subunit, was observed following addition of the
agonist aspirin-triggered resolvin D1 (Mottola, Chatterjee, Wu,
Chen, & Conte, 2017). Our own work identified FPR2 as the receptor
for annexin A1 (AnxA1), an anti-inflammatory protein and the same
receptor engaged by LXA4, which at the time was identified a proto-
typic anti-inflammatory endogenous mediator (Perretti et al., 2002). In
line with the degree of ligand specificity indicated above, for some
time, the genuine nature of FPR2 has remained unclear, with data
indicating pro-inflammatory properties following receptor activation
and other studies showing its anti-inflammatory activities upon activa-
tion on target cells and tissues (K. Chen et al., 2010; X. Chen
et al., 2019; Dufton et al., 2010; Liang et al., 2020). We now know
that the nature of the responses downstream of FPR2 activation is
more complex, yet the receptor could be genuinely indicated as a mas-
ter switch in promoting the resolution of inflammation.
2 | RESOLUTION OF INFLAMMATION AND
RESOLUTION PHARMACOLOGY
The resolution of inflammation reflects the integration of biological
processes that are operative in a protective and physiological inflam-
matory response, where the onset-to-peak phase of the host
response to injury and infection is followed by temporally appropriate
and controlled resolution, leading to the restoration of normal
tissue/organ function. In the context of pathological inflammation,
which is often chronic, or transient and relapsing, a low-grade inflam-
mation occurs. This ongoing low degree of inflammation is thought to
fail to set in motion the integrated processes of resolution (Serhan &
Savill, 2005). Therefore, it is of significant importance to identify pro-
cesses and mediators that are central to promote an active resolution.
As an example, incubation of human and mouse macrophages with
TNF-α induces FPR2 expression through de novo synthesis (Gobbetti
et al., 2014). Mediators, targets and processes of resolution have been
described in several excellent reviews and will not be reviewed here
(de Gaetano et al., 2018; Perretti, Cooper, Dalli, & Norling, 2017;
Serhan, 2014). What is important though is that FPR2 is able to pro-
mote several, if not all of the processes that characterise the resolu-
tion of inflammation biology, including blocking neutrophil
extravasation, promoting non-phlogistic monocyte recruitment, induc-
ing neutrophil apoptosis, enhancing macrophage phagocytosis as well
as macrophage efferocytosis, altering macrophage phenotype and, as
emerging more recently, instructing stromal cells to favour repair
(Perretti et al., 2017). We propose that in settings of chronic disease,
FPR2 might be able to reinstruct immune and tissue cells to favour, if
not the regaining of homeostasis a more stable status of allostasis.
Promoting resolution addresses a key unmet need given the chal-
lenges of insidious chronic inflammation that underpin numerous
prevalent diseases. The challenge is to harness FPR2 receptor activa-
tion towards developing novel medicines.
A few years ago, we have defined “resolution pharmacology” as a
new branch that will identify drugs developed on pro-resolving media-
tors and acting at pro-resolving receptors (Perretti, Leroy, Bland, &
Montero-Melendez, 2015). Important here is the new approach to
drug discovery for inflammatory diseases, since these new drugs
ought to be agonists and hence activate their receptor(s) and promote
a gene reprogramming that would change the phenotype of target
cells. This represents a 180 shift in the way one would treat chronic
diseases, promoting reparative processes instead of blocking a given
mediator or pathway (the latter is the approach taken over the last
100 years, with receptor antagonists, enzymatic inhibitors, anti-
cytokine biologics, etc.). Figure 1 presents this prediction in a sche-
matic way. First, activation of the pro-resolving receptor like FPR2 by
its agonists (e.g. two endogenously generated agonists indicated here,
AnxA1 and LXA4) sets in motion the integrated actions of resolution.
This cascade could involve also expression and/or release of other
pro-resolving mediators so that a reparative network of resolution is
then displayed in the target tissue. A relevant example here is the
release of IL-10 induced by AnxA1 and LXA4 as shown in the context
of gut inflammation (Souza et al., 2007) or liver fibrosis (Locatelli
et al., 2014). The latter study revealed another circuit of resolution,
whereby LXA4 induced AnxA1 expression as an endogenous pathway
to attenuate liver and kidney diseases in dysmetabolic settings of obe-
sity (Börgeson et al., 2015). Moreover, agents that elevate intracellular
cAMP can promote the synthesis of AnxA1 with a positive effect on
the resolution of experimental pleural inflammation (Lima et al., 2017).
Figure 1 illustrates another unique value of resolution biology, the
possibility to re-programme target cells to enable long-lasting repara-
tive and regenerative effects in the tissue of interest. This is a central
point for resolution pharmacology, to have a clinically beneficial effect
on curbing ongoing disease. The therapy ought to change the activity
and phenotype of target cells and ensure that the new subsumed sta-
tus remains consistent for some time.
Agonism at a pro-resolving receptor provides this unique oppor-
tunity with the potential to be a game changer in the context of
chronic diseases characterised by ongoing inflammatory processes.
The immune modulation induced by FPR2 activation includes attenua-
tion of signals coupled to IL-1β generation and downstream targets
including IL-6 (Brennan, Mohan, McClelland, Tikellis, et al., 2018).
These responses may be amenable to mimicry in the context of the
unmet need presented by the cytokine storm of coronavirus disease
2019 (COVID-19).
3 | FPR2 AS A PROTOTYPE TO KICK-START
RESOLUTION PHARMACOLOGY
An important cue now is how can one predict the pharmacological
properties on new molecules developed for agonism at a given pro-
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resolving receptor? We have recently reported that AnxA1 interacts
with FPR2 to activate a specific signalling cascade that leads to activa-
tion of AMPK (McArthur et al., 2020). The ability of AMPK signalling
to direct macrophage polarisation in the context of muscle injury
repair was known (Mounier et al., 2013); however, the inciting stimu-
lus upstream was not. We could demonstrate that FPR2 was the main
checkpoint here, with the agonist AnxA1 being provided by infiltrating
neutrophils. The ultimate outcome of the AnxA1/FPR2/AMPK path-
way resulted in the occurrence of a proper inflammatory reaction after
muscle injury, with recruitment of macrophages to the site of injury
and their polarisation towards an anti-inflammatory tissue-reparative
phenotype that ensured timely tissue repair and muscle regeneration.
Mice lacking AnxA1 showed impaired muscle repair after experimental
injury (McArthur et al., 2020). This study indicates that assessment of
AMPK phosphorylation downstream application of FPR2 agonists
(AnxA1 mimetics, LXA4 analogues or new chemical entities) could help
identify early whether an agonist at this receptor would be able to
polarise macrophages and promote tissue-reparative processes.
On a similar vein, we have demonstrated that LXA4 can drive
macrophage polarisation. In the context of experimental obesity, LXA4
attenuated the increased M1:M2 ratio observed in adipose, TNF-α
generation and downstream liver and kidney inflammation (Börgeson
et al., 2015). LXA4 treatment was associated with increased AnxA1.
Activation of AMPK has been shown to result in equivalent responses
of adipose liver and kidney in this system (Börgeson et al., 2017). In
mouse models of diabetes, LXA4 induced regression of atherosclerosis
and renal fibrosis. Altered gene expression patterns induced by LXA4
treatment in aorta (Brennan, Mohan, McClelland, de Gaetano,
et al., 2018) and kidney (Brennan, Mohan, McClelland, Tikellis,
et al., 2018) were consistent with a switch in phenotype of infiltrating
macrophages.
An interesting aspect emerged from the AMPK study, the fact
that FPR2 expression was markedly attenuated if not totally absent
from macrophages that had acquired a tissue-reparative mode. This
was evident both at the mouse level (with immunohistochemistry in
the damaged muscle and quantification of gene expression product in
sorted cells) and in human macrophages (McArthur et al., 2020). In the
latter case, cells lost FPR2 cell surface expression when polarised with
IL-4. These data indicate the possible existence of a fail-safe mecha-
nism whereby the AnxA1/FPR2/AMPK pathway cannot operate in
cells that have already switched their phenotype towards a pro-
resolving one. We hypothesise that such a mechanism will prevent an
overshooting of the pro-resolving signal and as such will avoid risks of
excessive dampening of inflammation. In sepsis, LXA4 decreases sys-
temic inflammation without compromising host defence and can
reduce pathogen virulence by inhibiting quorum sensing
(Wu et al., 2016). Investigation of single-nucleotide polymorphisms in
the FPR2 gene identified that the rs11666254 polymorphism was
F IGURE 1 Schematic representation of the integrated actions of pro-resolving mediators. Left panel: Annexin A1 and lipoxin A4 are
presented as exemplar ligands for formyl peptide receptor type 2 (FPR2), the pro-resolving receptor. By activating this GPCR, the two agonists
promote the integrated bioactions of resolution for a general reorganisation of the affected tissue or organ, to enable termination of inflammation
and regain of whole or partial tissue/organ functionality. Right panel, another distinctive element of pro-resolving therapeutics lies in the fact that
their agonistic activity can amplify their effects (see interwoven network of actions of the left) and promote reprogramming of target cells. This
would ensure (a) efficacy even when the agonist is no longer there, (b) a switch in cell phenotype or polarisation and (c) all-in-all longer-lasting
pharmacological efficacy. These characteristics require consideration for drug development with respect to pharmacokinetics, administration
route and frequency
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associated with decreased FPR2 mRNA and protein expression,
molecular changes that are functionally associated with susceptibility
to sepsis after traumatic injury (Zhang et al., 2017).
4 | RESOLUTION PHARMACOLOGY FROM
FPR2 BIOLOGY
We consider FPR2 the most intriguing pro-resolving receptor by far.
Mice lacking the receptor orthologues display often significant pheno-
types in settings of experimental diseases. We propose that to suc-
cessfully exploit the biology of resolution to guide the development of
novel molecules, one has to identify pro-resolving signalling cascades
that are conducive to the desirable pro-resolving actions. Early imple-
mentation of the appropriate predictive signal(s) at the level of pre-
clinical development will increase the chances of success for
molecules that will make it to clinical trial. As a consequence, defini-
tion and validation of the pro-resolving signalling readout must be
defined in the relevant target cells and applied early on in screening
programmes. Above, we have discussed exemplars of signalling path-
ways relevant to macrophage phenotype switch muscle injury repair,
regression of atherosclerosis and renal fibrosis. It is plausible that the
relevant pro-resolving signalling would be to some degree specific for
a given target cells, in a given disease setting. Figure 2 depicts this
observation with the example of macrophages and the need to apply
similar approaches to chondrocytes (if the endpoint is to develop
cartilage-regenerating therapies), fibroblasts (for anti-fibrotic
approaches), or other cell targets (e.g. alveolar macrophages for lung
allergy or gut epithelium for inflammatory bowel disease).
FPR2 agonists are being developed and tested also in man.
Indeed, the interesting biology of the receptor has stimulated a pleth-
ora of medicinal chemistry programmes, some reported in recent
reviews (Corminboeuf & Leroy, 2015; Perretti et al., 2015). The recent
resolution of the receptor in agonist-binding mode would certainly
favour further developments (T. Chen et al., 2020). Meanwhile, syn-
thetic lipoxin mimetics, which are FPR2 agonists, have been generated
and investigated in preclinical settings (de Gaetano et al., 2019). A
Phase I trial has been conducted with a small-molecule FPR2 agonist
developed by Actelion, compound ACT-389949 (Stalder et al., 2017).
More recently, Bristol-Meyers Squibb has concluded a Phase I trial for
a different small-molecule selective FPR2 agonist, compound BMS-
986235 (ClinicalTrials.gov Identifier NCT03335553). The medicinal
chemistry underpinning the development of this compound has
recently been published (Asahina et al., 2020) with the report of its tis-
sue protective properties in experimental heart failure. These
recent developments represent an exciting phase for determining
the effective potential that targeting FPR2 may offer for the devel-
opment of new therapies. It is interesting to note how the most
plausible application is for heart failure rather than pathologies
classically identified as inflammatory. In preclinical settings, AnxA1
has been shown to impact positively on macrophage remodelling in
the post-infarct heart, through induction of a pro-angiogenic mac-
rophage phenotype (Ferraro et al., 2019). Studies in large animals
with adenoviral delivery of AnxA1 confirmed this outcome. This
work is consistent with the study of Qin et al. (2017) who have
identified the heart-protective properties of first-generation FPR2
small-molecule agonists (compound 43 and compound 17b) in
acute myocardial infarct, proposing that a better outcome was
associated with a biased agonism against intracellular calcium fluxes
and in favour MAPK signalling cascade. More recently, García
et al. (2019) reported the reparative actions of a dual FPR1/FPR2
agonist used as a proof-of-concept tool. Given orally over a
4-week period, compound 43 afforded a high degree of protection
in a model of heart failure, linking beneficial outcomes for the
F IGURE 2 Pro-resolving receptor agonism to modify the phenotype of target cells. Our recent work has identified AMPK as the signalling
determinant downstream of formyl peptide receptor type 2 (FPR2) activation to switch the phenotype of muscle macrophages from a pro-
inflammatory to a pro-resolving reparative one (McArthur et al., 2020). This dataset prompts the hypothesis that definition of the signalling
pathways is of importance to accelerate the development of pro-resolving drugs, with the caveat that the relevant pathway may be cell and
disease specific. Here we depict macrophage FPR2 that responds to its agonists leading to macrophage switch. Moreover, the same need to
switch the phenotype of cells like fibroblasts and chondrocytes should prompt identification of the predictive signalling pathway conducive to the
wanted outcome, for example, not activating fibroblasts to myofibroblasts or anabolic chondrocytes
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animals to its ability to polarise macrophages towards a type 2 phe-
notype. It is unclear how this cellular phenotype overlaps with the
angiogenic macrophage promoted in the heart by AnxA1; in any
case, there is at least a partial overlap between the properties of
the synthetic and natural FPR2 agonists. We should note also that
the beneficial responses to FPR2 activation in infarction have not
been linked solely to tissue-mediated effect, for example, centred
on myocardial macrophages, but also to systemic responses, as
shown by the ability of the prototype peptide agonist WKYMVM
to mobilise angiogenic cells (Heo et al., 2017).
5 | CONCLUSION
While this discussion has focused on heart failure since motivated by
ongoing Phase II trials, we propose that FPR2 agonists can reap the
benefits of the biology of resolution of inflammation to re-programme
relevant target cells in a variety of diseased tissues. Thus providing a
fresh approach to the clinical management of several debilitating dis-
eases beyond those primarily affecting the heart. Early characterisa-
tion of FPR2 post-receptor signalling is required to incite the desirable
biological properties and it will expedite the drug development pro-
cess, while at the same time augmenting the chances of identifying
molecules that will have the correct pharmacodynamic properties. This
will increase the odds of efficacy in man, ultimately leading to patient
benefit. There is a growing appreciation that differential responses to
FPR2 activation may reflect agonist bias towards specific intracellular
pathways and that, as such, pro-resolving agonists may act as biased
allosteric modulators as recently shown for LXA4 (Ge et al., 2020).
FPR2 agonists may kick-start the establishment of “resolution pharma-
cology” as a new branch of the discipline, typified by agonists that re-
programme target cells to dampen ongoing inflammatory processes to
favour reparative and regenerative processes within the patients
themselves.
5.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018) and are permanently archived in the
Concise Guide to PHARMACOLOGY 2019/20 (Alexander
et al., 2019).
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